At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 901 enrolled
Drug / intervention
Aliskiren +3 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Aliskiren, Ramipril, and 2 other interventions for Hypertension. Completed, enrolled 901 participants across 1 site.
Detailed Summary
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartSep 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedAug 24, 2006
Enrollment StartSep 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.9 years ago
Interventions
Aliskirendrug
Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
Ramiprildrug
Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
Hydrochlorothiazidedrug
Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
Amlodipinedrug
Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning